All In Biotech

NDA 022578 · Kenvue Brands

Zyrtec Allergy

Cetirizine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Sep 3, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

32,663

24,436 serious, 5,137 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2025.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZYRTEC ALLERGY · CETIRIZINE HYDROCHLORIDE 10MG · TABLET, ORALLY DISINTEGRATING, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,660
  • pain8,999
  • fatigue8,984
  • alopecia7,543
  • rheumatoid arthritis7,476
  • abdominal discomfort7,469
  • systemic lupus erythematosus7,162
  • pemphigus7,032
  • off label use6,891
  • rash6,748
  • glossodynia6,536
  • swelling6,098

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200560
200620
200766
2008177
2009175
2010630
2011144
2012171
2013243
2014263
2015475
2016918
2017983
20181,105
20191,595
20202,186
20214,423
20224,445
20233,456
20244,314
20254,088
20262,707

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.